Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2016
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 11 Aug 2009 Actual patient number (40) added as reported by ClinicalTrials.gov.
- 14 Jul 2008 Actual end date is now 1 Nov 2007 as reported by ClinicalTrials.gov.
- 14 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.